GHRS | Ticker Profile - Titan Protect

GHRS

GH Research PLC

Healthcare · Biotechnology · NGM

$21.43

Data: 2026-05-15

✓ ETHICAL PASS

MOAT

MODERATE

Data Confidence: 57.1%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1.5B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-11.35

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-21.0%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$39.25

+83% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 8 analysts covering this stock

About GH Research PLC

GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

https://www.ghres.com

Country: Ireland Employees: 73 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PASS

Debt must be below 33% of total assets

Cash Ratio

18.7% PASS

Interest-bearing cash below 33% of assets

Receivables

0.0% PASS

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

0.678

Good returns relative to risk taken

Kelly Fraction

0.0490

Modest edge detected — smaller position warranted

Calmar Ratio

0.475

Drawdown risk outweighs the returns — higher risk profile

Annual Return

27.3%

Historical annualised return based on price data

Max Drawdown

-57.5%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.28

Moves slightly more than the broader market

52W High

$24.66

13% below the year high

52W Low

$10.66

101% above the year low

Avg Volume

215,651

Average daily shares traded — higher means easier to buy and sell

Short Ratio

9.0

Days it would take all short sellers to cover — higher means more crowded

Short % Float

8.0%

Moderate short interest

Div Yield

0.0%

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.79

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.00

Conservative use of debt — low financial risk

Current Ratio

34.13

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

33.65

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

N/A

Profit from core operations before interest and tax

Free Cash Flow

$-30,543,876

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-48,258,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$70.00

Target Median

$39.25

Target Low

$25.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-15

Before you go